Valneva plunges after Europe slashes Covid-19 vaccine order

After the EU significantly reduced the size of a supply agreement for Valneva’s alternative Covid-19 vaccine, investors have punished the French pharmaceutical firm on the stock exchange.

Photo: Lisi Niesner/Reuters/Ritzau Scanpix

Valneva SE fell as much as 15% after the European Union slashed its order of the French company’s Covid-19 vaccine.

European countries will now buy 1.25 million doses of Valneva’s vaccine after amending a previous purchasing agreement that called for 27 million doses in 2022 and as many as 60 million over two years.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs